A client wanted to assess the retinal toxicity of two lead compounds and determine how each impacts the retina.
Image Credit: Newcells Biotech
Solution
Step 1:
Newcells’ experts worked with the client to understand the problem
The client required a retina model to quickly assess the retinal toxicity of two compounds and identify any differences. Newcells recommended studying how each chemical impacts cell viability and cellular composition in its iPSC-derived retinal organoid model.
Step 2:
Newcells created a study protocol and design that efficiently provided data of value
The experiment investigated compound-induced toxicity on mature, healthy retinal organoids differentiated for 150 days and exposed for 72 hours.
The readouts included retinal organoid viability assays and immunofluorescence with six important retinal markers to assess organoid cell composition (ganglion cells, photoreceptors, amacrine cells, horizontal cells, and Muller glia).
Step 3:
From initiation to data in less than two months
The study comprised the experimental phase, data processing and analysis, and a data summary presentation.
DATASET: Four compounds, one positive control, a hundred retinal organoids, seven immunofluorescence staining per compound, ATP depletion, and LDH release for each compound.
The study was finished in just under two months.
Step 4:
Newcells delivered a detailed report with a reliable dataset
Newcells provided a strong dataset that included a large number of immunofluorescence images.
Outcomes for the client
The study confirmed one of the compounds’ retinal toxicity and provided the client with a deeper understanding of how the compound impacts various cell types.
About Newcells Biotech
Newcells Biotech develops in vitro cell-based assays for drug and chemical discovery and development.
Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology, and organoid technology, we build models that incorporate the “best biology” for predicting in vivo behavior of new drugs.
Our experts have developed and launched assays to measure transporter function, safety, and efficacy in a range of cell and tissue types, including kidney, retina and lungs.
We have the capability to develop and implement protocols to measure cilia beat frequency and toxicity on small airway epithelial cells model, retinal toxicity and disease modelling on retinal organoids and retina epithelium, as well as drug transport in the kidney, DDI and nephrotoxicity across human and a range of preclinical species.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.